Press release
Creative Bioarray Unveils Comprehensive Histology Services to Accelerate the Projects in Biochemical Research
New York, June, 2020 - Creative Bioarray, the world’s leading biotechnology products and services provider, recently announced its implementation on the histology services with more comprehensive services including immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), fluorescent in situ hybridization (FISH), and transmission electron microscopy.Creative Bioarray has already confirmed the capability to produce high-quality and reproducible IHC stained slides with unparalleled efficiency. The entire IHC team has been fully trained to operate and maintain the machine and is ready to put the system to good use. The strategy and experimental design offered by Creative Bioarray will best fit specific needs and herein to accelerate the speed of research goals. Meanwhile, the customized service that will dramatically reduce operating costs by eliminating the complicated time-consuming processes of ISH also is available. The routine and custom ISH services are flexible to meets the needs ranging from tissue sections preparation to probe design, labeling and purification, as well as further hybridization and ISH staining.
Drawing on many years of experience and in-depth knowledge, Creative Bioarray can fully understand the advantages and pitfalls of fluorescence in situ hybridization (FISH), therefore offering fluorescence in situ hybridization (FISH) service range from standardized testing of validated assays to custom development of new assays. With excellent in-house scientists and experts who have years of experience in histology and FISH, Creative Bioarray can guarantee the speed, quality and cost of FISH service.
M-FISH is a general-purpose tool for precise chromosome separation and rapid chromosome classification, helping to speed up the workflow. Complementing standard cytogenetic methods, it helps to decipher complex chromosomal rearrangements and is used to identify non-random structural chromosomal rearrangements that other methods cannot detect. M-FISH characterizes genomic changes in many tumor cell lines. M-FISH offered in Creative Bioarray has unparalleled advantages: such as rapid analysis of mid-term diffusion, and the ability to analyze complex cases with multiple chromosome rearrangements and identify marker chromosomes, to distinguish between different imbalances that can be detected in aCGH, and it can also accurately karyotype a single midterm without selection.
“Our company is committed to providing consistent, high-quality histology services with quick turn-around times to the international scientific research community.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “whether it is a pilot project requiring custom protocol development or a large-scale multi-timepoint drug efficacy study, each project is individually customized and undergoes the strictest of quality control measures before being presented back to our valuable client.”
45-1 Ramsey Road, Shirley, NY 11967, USA
About Creative Bioarray
Creative Bioarray is a global drug discovery and development service company providing professional platforms to advance oncology, drug development, and many other disease research. With an extensive portfolio of relevant research models and predictive tools, Creative Bioarray enables itself to work with clients within the Drug Development, Medical Device, Pharmaceutical, Government, and Academic sectors.
For more information, visit: https://www.creative-bioarray.com/.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Creative Bioarray Unveils Comprehensive Histology Services to Accelerate the Projects in Biochemical Research here
News-ID: 2083237 • Views: …
More Releases from Creative Bioarray
Creative Bioarray Launches Primary Adipocytes in Order to Accelerate Drug Screen …
Creative Bioarray, one of the world’s leading biotechnology provider whose mission focuses on developing high quality products and services that can be applied to accelerate the investigation of life science research, recently it announced the launch of primary adipocytes in order to promote the development of drug screening and therapeutical development.
The role of adipose cells is not just to store fat. They also play a role in metabolic diseases. By…
Creative Bioarray Releases Several Types of Human Cardiac Cells to Promote The T …
Creative Bioarray, the world’s leading biotechnology products and service provider, focuses on developing high quality products and satisfatory services to accelerate life sciences research, solve complex analytical challenges and increase laboratory productivity. Recently, Creative Bioarray announced the release of its human cardiac cells to support therapeutic interventions of cardiovascular disease.
A single cardiomyocyte represents the smallest fully functional model system of the myocardium and can be used to examine force production,…
Creative Bioarray Expanded Its Stem Cell Products Variety
Creative Bioarray expanded its stem cell products variety in human adult stem cells, mouse adult stem cells, and adipose-derived stem cells last Monday.
Long Island City, New York, April 13, 2016 -- Creative Bioarray a professional cells supplier announced its expansion on human stem cell products. And now in total there are five categories of adult stem cells. This expansion is a sign of comprehensive increase in stem cell products line.
In…
More Releases for ISH
How big is In-Situ Hybridization (ISH) Market?
A new Report by DataM Intelligence, titled "In-Situ Hybridization (ISH) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the In-Situ Hybridization (ISH) market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The In-Situ Hybridization…
In-situ Hybridization (ISH) Market Analysis and Future Prospects for 2030
The world of the in-situ hybridization (ish) market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
In Situ Hybridization (ISH) Market Research Report 2015-2025
About the Global In Situ Hybridization (ISH) Market Research Report 2015-2025:
Global In Situ Hybridization (ISH) Market Research Report 2015-2025 is divided into various key segments like device type, material, applications, and end users. The report is thoroughly analyzed and studied by the researchers to offer deep insights on each of these segments with statistics. This information is beneficial for the manufacturers in the industry to plan their policies and strategies…
In Situ Hybridization (ISH) Market to Record an Exponential CAGR by 2025
Researchmoz added Most up-to-date research on "In Situ Hybridization (ISH) Market to Record an Exponential CAGR by 2025" to its huge collection of research reports.
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small…
Ish Spencer Becomes Managing Director and Partner at US Capital Partners
Private investment bank promotes senior executive to partnership level, following another year of strong growth at the firm.
San Francisco, CA, USA, March 16, 2016 -- US Capital Partners Inc. is pleased to announce the recent appointment of Ish Spencer as Managing Director and Partner at the firm. Headquartered in San Francisco, US Capital Partners is a private investment bank that makes direct debt investments between $500,000 and $100 million, participates…
Showcase of World’s first self-powered CO2 Sensor at ISH 2011
EnOcean Alliance member Gas Sending Solutions (GSS) announces first commercially available wireless CO2 sensor for sustainable buildings
Cumbernauld, Scotland, 2 March 2011 — Gas Sending Solutions (GSS) will showcase the world’s lowest power CO2 gas sensor enabled by revolutionary EnOcean self-powered wireless technology at ISH 2011 – the leading international trade fair for innovative bathroom design, energy efficient heating and air-conditioning technology and renewable energies – taking place in Frankfurt, 15-19…